GABAergics & Anxiolytics

Navigation

Upward Index: 02 - Compounds & Molecules MOC | Literature Dossier: GABAergics & Anxiolytics - References

---

1. Pharmacodynamics & Mechanism of Action

The balance between excitatory Glutamate and inhibitory $\gamma$-Aminobutyric Acid (GABA) governs cortical signal-to-noise ratio, autonomic arousal, and sleep architecture. Unlike classical benzodiazepines or phenibut—which directly bind ${\text{GABA}}_{\text{A}}$ $\alpha /\gamma$ or ${\text{GABA}}_{\text{B}}$ subunits and induce rapid receptor uncoupling, tolerance, and rebound excitotoxicity—biohacking anxiolytics target enzymatic GABA turnover, competitive glutamate blockade, or neurosteroidogenesis.

• L-Theanine ($\gamma$-Glutamylethylamide): Structural analog of L-glutamate and L-glutamine that crosses the BBB via the LAT1 transporter. Acts as a low-affinity competitive antagonist at AMPA, Kainate, and NMDA glutamate receptors, inhibits neuronal glutamine transporters (SNAT1), increases striatal/hippocampal GABA and glycine, and generates $8\text{–}13\text{ Hz}$ Alpha-band EEG oscillations within $30\text{–}45\text{ minutes}$ (“wakeful relaxation”).
• Lemon Balm (Melissa officinalis — Rosmarinic Acid): Potently inhibits GABA Transaminase (GABA-T)—the mitochondrial enzyme that degrades synaptic GABA into succinic semialdehyde—preserving endogenous synaptic GABA pools without direct receptor desensitization.
• Magnolia Bark (Honokiol & Magnolol) & Apigenin:
  • Honokiol / Magnolol: Allosterically modulate ${\text{GABA}}_{\text{A}}$ ${\alpha }_2/{\alpha }_3$ subunits (anxiolytic without ${\alpha }_1$-mediated motor ataxia) and activate Cannabinoid ${\text{CB}}_1/{\text{CB}}_2$ receptors to shorten NREM sleep latency.
  • Apigenin: Flavone that binds the benzodiazepine site on ${\text{GABA}}_{\text{A}}$ receptors and inhibits CD38 (sparing intracellular ${\text{NAD}}^{+}$).
• Emoxypine Succinate (Mexidol) & Etifoxine (Stresam):
  • Emoxypine: 3-hydroxypyridine succinate derivative structurally analogous to Vitamin B6; increases membrane fluidity around the ${\text{GABA}}_{\text{A}}$ receptor complex—enhancing the binding affinity of endogenous GABA ($+35\text{–}50\%$) without binding the receptor itself.
  • Etifoxine: Non-benzodiazepine anxiolytic that binds the ${\beta }_2/{\beta }_3$ subunit of ${\text{GABA}}_{\text{A}}$ and activates the mitochondrial Translocator Protein (18 kDa TSPO), stimulating endogenous neurosteroid synthesis (Allopregnanolone), which provides potent anxiolysis without tolerance or dependence.
• Picamilon ($N$-Nicotinoyl-GABA): Synthetic conjugate of Niacin (Vitamin B3) and GABA that crosses the BBB intact before hydrolyzing into vasodilatory niacin and inhibitory GABA.

---

2. Pharmacokinetics & Safety / Tolerance Matrix

Compound	Primary Target	Tolerance / Withdrawal Risk	Daytime Cognitive Impact
L-Theanine	AMPA/NMDA blockade + Alpha EEG	None	Enhances attentional switching; eliminates caffeine vasoconstriction & jitteriness
Emoxypine (Mexidol)	Membrane lipid modulation of ${\text{GABA}}_{\text{A}}$	None (resensitizes ${\text{GABA}}_{\text{A}}$ receptors)	Non-sedating; neuroprotective & mitochondrial succinate donor
Lemon Balm (Cyracos)	GABA Transaminase (GABA-T) inhibitor	Very Low	Mildly calming at $300\text{ mg}$; sedative at $600\text{ mg}$
Etifoxine	${\text{GABA}}_{\text{A}}$ ${\beta }_2/{\beta }_3$ + TSPO (Allopregnanolone)	None (clinical parity with lorazepam without rebound)	Non-sedating anxiolytic ($50\text{ mg}$ TID)
Magnolia Bark	${\text{GABA}}_{\text{A}}$ PAM + ${\text{CB}}_1/{\text{CB}}_2$	Moderate if used nightly $>4\text{ weeks}$	Sedative; best reserved for sleep onset or acute evening cortisol spikes

---

3. Dosing, Cycling & Synergies

• Standard Protocol:
  • Daytime “Focused Calm” Stack: $200\text{ mg}$ L-Theanine + $100\text{ mg}$ Caffeine ($2:1$ ratio) + $125\text{–}250\text{ mg}$ Emoxypine Succinate.
  • Evening Sleep Architecture Stack (Huberman-style): $100\text{–}300\text{ mg}$ L-Theanine (omit if vivid dreams/sleepwalking occur) + $50\text{ mg}$ Apigenin + Magnesium Forms & Bioavailability ($200\text{ mg}$ elemental Mg Bisglycinate/L-Threonate).
  • Acute Autonomic Downregulation: $300\text{–}600\text{ mg}$ Lemon Balm ($>7\%$ rosmarinic acid) or $50\text{–}100\text{ mg}$ Picamilon.
• Cycling Cadence: L-Theanine, Apigenin, and Emoxypine can be used daily; cycle direct ${\text{GABA}}_{\text{A}}$ PAMs like Magnolia Bark ($200\text{–}400\text{ mg}$) on an intermittent schedule (2–3x/week). Avoid chronic Phenibut (${\text{GABA}}_{\text{B}}$ / ${\alpha }_2\delta$ VGCC ligand) due to rapid tolerance and severe withdrawal.
• Contraindications & Biomarkers to Monitor:
  • Contraindications: Lemon Balm can inhibit TSH binding to thyroid receptors at high chronic doses (caution in hypothyroidism); Etifoxine carries a rare risk of idiosyncratic transaminase elevation (monitor ALT/AST).
  • Biomarkers: Nocturnal HRV (RMSSD), Resting Heart Rate, EEG Alpha/Beta Ratio, PSQI / Oura/Whoop Deep & REM Sleep Metrics, and TSH/Free T3 (with chronic Lemon Balm).

---

4. Key Scientific Evidence Summary

• L-Theanine Autonomic Stress Blunting: Kimura et al. (2007) demonstrated in Biological Psychology that $200\text{ mg}$ L-Theanine significantly reduced heart rate, salivary immunoglobulin A (s-IgA) stress reactivity, and sympathetic LF/HF HRV ratios during acute mental arithmetic stress ($p<0.05$).
• L-Theanine + Caffeine Synergy: Owen et al. (2008) showed in a double-blind crossover trial ($N=27$) that combining $100\text{ mg}$ L-Theanine with $50\text{ mg}$ caffeine significantly improved both speed and accuracy on an attention-switching task and reduced susceptibility to distraction compared to caffeine alone ($p<0.01$).
• Lemon Balm & Chronic Stress/Insomnia: Cases et al. (2011) demonstrated that 15 days of $600\text{ mg/day}$ standardized Melissa officinalis extract (Cyracos) reduced anxiety manifestations by $-18\%$ and insomnia by $-42\%$ ($p<0.01$).

See full study breakdowns in GABAergics & Anxiolytics - References.